biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by jdstoxon Jun 19, 2020 8:43am

127 Views

Post# 31168394

RE:RE:Feuerstein-Ratain Rule

I find, minedigger, that many readers here prefer more in-depth content, something that you, yourself, have suggested that I stick to.

I think it's time to let you tout that ridiculous FR Rule all by yourself. You're so geared up to set me on my butt that you can't even figure out what the inevitable results of that rule would be if it did have any validity.

Here's a question for you. How many microcaps become mid to large caps after successful p1 and p2 trials and would therefore be excluded from FR's myopic examinations?

I suspect that you are smart enough to realize the glaring fallacious nature of the Feuerstein-Ratain Rule and what it would mean if it were widely believed.

jdstox

Bullboard Posts

5 steps to mastering risk management in the stock market